Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (14780)	9/20/2000 2:22:07 PM
From: Cacaito	Respond to of 17367

Rk, problem was,I bought xoma looking for $5B not $0.5B rbpi21 as a treatment of septic shock, not infections. Of course, a new successful antibiotic against resistant strains is more than welcome. I am back again in Icos, could not get below $50 even with big Monday drop, they will have $0.5B from Cialis the viagra me too drug (sure thing), and the antishock-antiards will bring the other $4.5B, better capitalized, less dilution in the future, just for comparison of risks.

To: Robert K. who wrote (14780)	5/9/2001 12:58:08 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Bob look where this guy did his residency training AND his past at XOMA. BTW, I just saw George setting up the Lemonade stand in front of the Wohankateer clubhouse. He was mumbling something about a long hot summer.>>>>>>>>>>>Corgentech Announces Appointment of Todd J. Lorenz, M.D., as Chief Medical Officer SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire/ -- Corgentech, Inc., a privately-held biotechnology company, announced today that Todd J. Lorenz, M.D., has been appointed Chief Medical Officer. Dr. Lorenz joins Corgentech from Cor Therapeutics, Inc., where he served as its Vice President of Medical Affairs. Dr. Lorenz will be responsible for all of Corgentech's clinical development activities, focusing primarily on its lead product, the E2F Decoy, a combination drug and device designed to prevent vein grafts used in coronary and peripheral bypass procedures from occluding and failing. The U.S. Food and Drug Administration (FDA) granted "fast track" designation for the E2F Decoy in March. "Dr. Lorenz's has a breadth of experience developing products, specifically those designed to treat arterial occlusion," said John P. McLaughlin, Corgentech's President and Chief Executive Officer. "He will be enormously helpful as we move the E2F Decoy program into Phase III trials and other research candidates into clinical development." Previously, Dr. Lorenz served as Vice President of Medical Affairs at Cor Therapeutics where he managed clinical development activities and was focused primarily on the development and regulatory review of the company's first product, INTEGRILIN(TM), which was approved for marketing by the FDA in May 1998 for acute coronary syndromes. Prior to his tenure at Cor, he served as Director of Clinical Development at Xoma Corporation. Before that, he was in private practice, and also served as a clinical consultant for Highland General Hospital's Department of Endocrinology in Oakland, Calif. Dr. Lorenz has authored numerous abstracts and publications that have appeared in such prestigious journals as the 'American Journal of Cardiology', 'Journal of the American College of Cardiology', 'Circulation', 'Journal of the Society of Thoracic Surgery', 'The Lancet' and 'The New England Journal of Medicine'. He received his medical degree from Case Western Reserve University and completed his residency in internal medicine at The University of Texas, Southwestern. He also completed a fellowship in endocrinology at the University of California, San Francisco. About Corgentech Inc. Corgentech, Inc., is a privately-held biotechnology company committed to the discovery, development and commercialization of novel molecular- and genetic-based therapies for the treatment of cardiovascular and other serious diseases. The Company's lead product, the E2F Decoy, is designed to prevent vein grafts used in coronary artery and peripheral arterial bypass procedures from blocking and failing and is in the advanced stages of clinical development. Leveraging its leadership in pressure-mediated transfection of decoy oligonucleotides to regulate transactivation of genes, Corgentech's research engine is focused on other promising therapeutic targets to provide treatments for other serious unmet medical needs. For more information on the company and its technology, visit www.corgentech.com.<<<<<<<<<<<<<<<<<<

To: Robert K. who wrote (14780)	11/10/2002 12:19:43 AM
From: Bluegreen	Respond to of 17367

Well, well, well, look at this>>>>>>>>>>>>>>>> ragingbull.lycos.com

To: Robert K. who wrote (14780)	1/8/2003 12:24:42 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Has anyone here read not just this abstract but the entire paper? >>>>>>>>>>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12014429&dopt=Abstract

To: Robert K. who wrote (14780)	12/4/2003 9:38:14 PM
From: Bluegreen	Respond to of 17367

Bob, who keeps track of Raptiva scripts? Is it one company or many? Does a regular pharmacy stock it?

To: Robert K. who wrote (14780)	5/6/2004 12:20:44 PM
From: Bluegreen	Respond to of 17367

ALERT!!!!!!!!!!!!!!!!!! ALERT!!!!!!!!!!!!!!! COULDN'T this DESTROY THE BPI MARKET????????? UNBELIEVABLE FIND!!!!!!!! ONE OF MY BEST EVER!!!!!! IS THIS HORRIBLE NEWS FOR XOMA?????? I wonder how cheap China can make this stuff???? WHY isn't EVERYONE SHORTING THIS PIG????? First the ENBREL COMPETITION AND NOW THIS FROM CHINA!!!!!! How is Xoma EVER going to become profitable???? You don't see SCANNON buying at these prices!!!!!!! Thanks Scannon for the MESSAGE you are sending by FLIPPING THOSE OPTIONS!!!!!!>>>>>>>>>>>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15099530

To: Robert K. who wrote (14780)	5/12/2004 11:07:35 PM
From: Bluegreen	Respond to of 17367

Bob, have you ever heard of Timessquare capital mgnt?????http://www.nasdaq.com/asp/Holdings.asp?mode=&kind=&symbol=xoma&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&symbol=&FormType=&mkttype=&pathname=&page=holdingssummary&selected=XOMA

To: Robert K. who wrote (14780)	7/2/2004 12:08:34 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Bob, so what is the status of this?>>>“This pilot study is the first in a series of potential probe studies XOMA is considering to explore various indications for NEUPREX®,” said John L. Castello, XOMA’s chairman, president and chief executive officer. “We believe NEUPREX® has established a promising safety and activity profile in clinical trials involving over 2000 patients in a variety of indications. We’re pleased that Children’s Medical Center Dallas physicians also believe that it could potentially be a beneficial treatment for pediatric patients undergoing extensive surgical interventions and look forward to reviewing the results following the study’s completion." About Congenital Heart Disease, Open Heart Surgery (OHS) and Cardiopulmonary Bypass (CPB) Every year, an estimated 35,000 babies are born with some form of congenital heart disease. More than twice as many children die from congenital heart disease in the U.S. each year than from childhood cancers. Approximately one-third of children born with congenital heart disease will require surgery in the first year of life. The majority, more than 6,000 infants each year, will require complex open heart surgery (OHS) which necessitates the use of cardiopulmonary bypass (CPB), a heart-lung bypass machine. During CPB, the heart-lung machine takes over the functions of the heart and lungs (which have been cooled down and stopped), allowing a surgeon to operate on the heart while the machine sustains circulation. However, CPB itself poses significant risks which are particularly prominent in pediatric patients. CPB induces a systemic inflammatory response associated with increasing blood levels of endotoxin and causes damage to children’s immature organ systems including the heart, lungs, kidneys and brain. The incidence of complications associated with pediatric OHS patients undergoing CPB ranges from 25-60 percent, with the inflammatory response to CPB causing a prolonged need for mechanical ventilation and heart medications, and additionally bleeding complications and multiple organ failure. All of these post-operative complications can impair patient recovery, resulting in extended hospital stays and increased medical expenses.<<<<<<<<